Special Issue

Targeted Therapy of Pediatric Cancer

Message from the Guest Editors

Today, more than 80% of children diagnosed with cancer can be cured. However, cancer remains one of the leading causes of death in children and adolescents. Global (epi)genetic NGS sequencing approaches have demonstrated that pediatric tumors are fundamentally different from adult malignancies. They have also identified potentially druggable mutations in 25-50% of pediatric tumors. These results led to novel targeted and immunotherapeutic treatment approaches. However, it must also be noted that for many tumor entities, effective therapy approaches have not yet been identified. However, their development is very dynamic and new pre-clinical models such as PDX models and 3D cultures of primary tumor material, as well as phase II clinical trials of targeted therapeutics, are driving this development, giving rise to the hope that these treatments have the potential to improve cure rates. The purpose of this Special Issue is to review the current developments in the field of molecular therapies, to highlight advances in the use of targeted drugs and immunotherapies, and to point out problems that still need to be solved for the treatment of pediatric tumors.

Guest Editors

Prof. Dr. Günther H.S. Richter

Department of Paediatrics, Division of Oncology and Haematology, Charité—Universitätsmedizin Berlin, 13353 Berlin, Germany

Prof. Dr. Beat W. Schäfer

Department of Oncology, University Children's Hospital Zurich, 8032 Zurich, Switzerland

Deadline for manuscript submissions

closed (20 February 2024)



Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/167302

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

